샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737354

망상신경섬유종 치료 시장

Plexiform Neurofibromas Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 372 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

망상신경섬유종 치료 세계 시장은 2030년까지 18억 달러에 달할 전망

2024년에 12억 달러로 추정되는 망상신경섬유종 치료 세계 시장은 2024-2030년 분석 기간 동안 CAGR 6.5%로 성장하여 2030년에는 18억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 셀루메티닙은 CAGR 5.0%를 기록하며 분석 기간 종료시에는 6억 3,240만 달러에 달할 것으로 예측됩니다. 비스테로이드성 항염증제 부문의 성장률은 분석 기간 동안 CAGR 8.1%로 추정됩니다.

미국 시장은 추정 3억 3,500만 달러, 중국은 CAGR 10.0%로 성장 예측

미국의 망상신경섬유종 치료 시장은 2024년에 3억 3,500만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 10.0%를 뒤쫓아 2030년에는 예측 시장 규모 3억 6,520만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.3%와 6.3%로 예측됩니다. 유럽에서는 독일이 CAGR 4.3%로 성장할 것으로 예측됩니다.

세계의 망상신경섬유종 치료 시장 - 주요 동향과 촉진요인 정리

희귀종양 관리 및 유전성 질환 치료에서 망상신경섬유종 치료가 급증하는 이유는 무엇일까?

신경섬유종(PN)은 양성이지만 종종 쇠약하게 만드는 종양으로 NF1 유전자의 돌연변이로 인해 발생하는 유전성 질환인 제1형 신경섬유종증(NF1)과 관련이 있습니다. 이 종양은 말초신경을 따라 발생하며 주변 조직을 침범하여 통증, 기형, 운동 제한, 기도 폐쇄 및 악성화와 같은 생명을 위협하는 합병증을 유발할 수 있으며, PN의 치료는 역사적으로 외과적 절제술로 제한되어 왔지만, 종양이 미만성 및 침습성이기 때문에 높은 재발률과 신경 손상의 위험을 수반합니다.

표적 치료제, 특히 셀루메티닙과 같은 MEK 억제제의 도입은 PN 관리의 패러다임 전환을 가져왔습니다. 증상이 있고 수술이 불가능한 PN을 가진 소아 환자를 대상으로 FDA 승인을 받은 셀루메티닙은 NF1 돌연변이의 다운스트림에 있는 MAPK 경로를 억제하여 종양 부피 감소와 증상 개선을 가져옵니다. NF1에 대한 임상적 이해가 깊어짐에 따라 신경종양학 및 유전학 분야의 광범위한 분야에서 NF1에 대한 치료법 개발이 가속화되고 있으며, 이는 PN을 축소시키는 효과가 입증된 최초의 약물 치료제로서 수술과 지지요법에만 의존하던 환자들에게 새로운 희망을 주고 있습니다.

NF1 관련 종양의 치료 옵션을 넓히는 약물 개발 및 유전자 표적 치료란?

새로운 MEK 억제제(트라메티닙, 비니메티닙 등), mTOR 억제제, 효능을 개선하고 내성 메커니즘을 해결하기 위해 고안된 병용요법으로 임상 파이프라인이 확대되고 있습니다. 성인 PN 환자에서 이들 약물의 안전성과 유효성을 평가하기 위한 임상시험이 진행 중이며, 면역요법 및 방사선 치료와의 병용요법도 검토되고 있습니다. 현재 진행 중인 바이오마커 연구는 반응자를 식별하고, 최소한의 독성으로 최대의 종양 조절을 달성할 수 있도록 용량을 최적화하는 것을 목표로 하고 있습니다.

이와 함께 NF1 유전자 및 그 다운스트림 이펙터를 표적으로 하는 유전자 편집 요법이나 안티센스 올리고뉴클레오티드(ASO) 요법이 전임상 단계에 진입하고 있습니다. 이러한 접근법은 단순히 증식 신호전달을 억제하는 것이 아니라 그 기저에 있는 유전적 기능장애를 교정하고자 하는 것입니다. 또한, 환자 유래 이종 이식편과 오가노이드 모델은 PN의 거동을 시뮬레이션하고 맞춤형 의료의 틀에서 새로운 화합물을 평가하기 위해 사용되고 있습니다. 체적 MRI와 같은 첨단 영상 진단 방법도 시간 경과에 따른 종양 부하와 반응을 정확하게 측정하여 치료 모니터링을 강화할 수 있게 되었습니다.

전 세계적으로 치료 수요와 혁신을 주도하는 환자 집단과 연구기관은?

소아 NF1 환자는 가장 큰 초기 치료 코호트이며, 특히 기능 장애, 통증, 해부학적 구조 왜곡, 증상이 있는 수술이 불가능한 PN을 가진 환자들이 가장 큰 초기 치료 코호트입니다. 진행성 PN을 앓고 있거나 악성 말초신경초종양(MPNST)으로 전이될 위험이 높은 성인은 치료 중재의 이차적 대상 집단으로 부상하고 있습니다. 신경섬유종증 종합센터, 소아종양병원, 임상연구기관이 환자 모집, 치료 시험, 데이터 수집을 주도하고 있습니다.

북미, 특히 미국은 NIH, Children's Tumor Foundation, 주요 대학병원 등의 기관이 지원하는 NF1 연구와 의약품 승인 활동의 중심지입니다. 유럽도 활발하여 독일, 프랑스, 영국의 연구 거점들이 유럽 희귀 신경질환 조사 네트워크(European Reference Network for Rare Neurological Diseases)와 같은 컨소시엄을 통해 공동 임상시험을 진행하고 있습니다. 아시아태평양에서는 인지도와 진단율의 증가가 수요를 뒷받침하고 있으며, 관찰 연구와 초기 단계의 임상시험에 대한 참여가 증가하고 있습니다. 유전자 스크리닝이 일상화됨에 따라 PN 환자의 식별과 관리가 전 세계적으로 크게 확대될 것으로 예상됩니다.

망상신경섬유종 치료 시장의 장기적인 성장과 전략적 발전의 원동력은 무엇인가?

망상신경섬유종 치료 시장의 성장 원동력은 유전자 연구의 발전, 희귀질환 치료제에 대한 정책적 인센티브, 희귀질환 치료에 대한 옹호론이 증가하고 있습니다. 규제 당국이 획기적인 치료법에 대한 신속한 경로를 제공함에 따라 제약사들은 미충족 수요를 충족시키는 고정밀 의약품에 투자하고 있습니다. 희귀의약품 지정, 시장 독점권, 소아 우선 심사 바우처는 기술 혁신을 촉진하고 효과적인 PN 치료제의 시장 출시 시간을 단축하고 있습니다.

전략적으로, 바이오 제약사들은 치료법 개발 및 상용화를 위해 학술 센터, 환자 지원 단체, 유전체 데이터 플랫폼과 파트너십을 맺고 있습니다. NF1에 대한 임상 및 환자 커뮤니티에서 NF1에 대한 인식이 높아짐에 따라 조기 진단 및 개입이 우선순위가 되고 있으며, 의미 있는 종양 조절, 삶의 질 개선, 장기 관해의 가능성을 제공하고 있습니다. 장기 관해의 가능성을 제공하는 새로운 치료법에 대한 수요가 증가하고 있습니다. 이러한 새로운 치료 영역에서 PN은 의학적 과제일 뿐만 아니라 복잡한 유전성 질환을 치료하는 혁신의 관문이기도 합니다.

부문

약물 종류(셀루메티닙, 비스테로이드성 항염증제, 항경련제, 기타 약물 종류), 인구통계(소아, 성인), 판매 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 사례(총 39개사)

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb
  • CureAge Therapeutics
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche Holding AG
  • Sanofi S.A.
  • SpringWorks Therapeutics, Inc.
  • Takeda Pharmaceutical Company

관세 영향 계수

Global Industry Analysts는 본국, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 하락, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.12

Global Plexiform Neurofibromas Treatment Market to Reach US$1.8 Billion by 2030

The global market for Plexiform Neurofibromas Treatment estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Selumetinib, one of the segments analyzed in the report, is expected to record a 5.0% CAGR and reach US$632.4 Million by the end of the analysis period. Growth in the Non-Steroidal Anti-Inflammatory Drugs segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$335.0 Million While China is Forecast to Grow at 10.0% CAGR

The Plexiform Neurofibromas Treatment market in the U.S. is estimated at US$335.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$365.2 Million by the year 2030 trailing a CAGR of 10.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Plexiform Neurofibromas Treatment Market - Key Trends & Drivers Summarized

Why Is Plexiform Neurofibromas Treatment Gaining Urgency in Rare Tumor Management and Genetic Disorder Care?

Plexiform neurofibromas (PNs) are benign but often debilitating tumors associated with Neurofibromatosis Type 1 (NF1), a genetic disorder caused by mutations in the NF1 gene. These tumors can develop along peripheral nerves and infiltrate surrounding tissues, leading to pain, disfigurement, mobility limitations, and potentially life-threatening complications such as airway obstruction or malignant transformation. Treatment for PNs has historically been limited to surgical excision, which carries high recurrence rates and risks of nerve damage due to the tumor’s diffuse and invasive nature.

The introduction of targeted therapies-most notably MEK inhibitors such as selumetinib-has marked a paradigm shift in PN management. Approved by the FDA for pediatric patients with symptomatic, inoperable PNs, selumetinib inhibits the MAPK pathway downstream of the NF1 mutation, leading to tumor volume reduction and symptomatic improvement. This is the first pharmacologic treatment with demonstrated efficacy in shrinking PNs, offering new hope for patients previously reliant solely on surgery or supportive care. As clinical understanding of NF1 deepens, therapeutic development for PNs is accelerating within the broader field of neuro-oncology and genetic medicine.

How Are Drug Development and Gene-Targeted Therapies Expanding Treatment Options for NF1-Related Tumors?

Clinical pipelines are expanding with new MEK inhibitors (e.g., trametinib, binimetinib), mTOR inhibitors, and combination regimens designed to improve efficacy and address resistance mechanisms. Trials are underway to assess their safety and effectiveness in adult PN patients, as well as in combination with immunotherapies or radiologic interventions. Ongoing biomarker studies aim to identify responders and optimize dosage for maximal tumor control with minimal toxicity.

In parallel, gene-editing and antisense oligonucleotide (ASO) therapies targeting the NF1 gene or its downstream effectors are entering preclinical development. These approaches seek to correct the underlying genetic dysfunction rather than merely inhibit proliferative signaling. Additionally, patient-derived xenografts and organoid models are being used to simulate PN behavior and evaluate new compounds in a personalized medicine framework. Advanced imaging modalities like volumetric MRI are also enhancing treatment monitoring by enabling precise measurement of tumor burden and response over time.

Which Patient Populations and Research Institutions Are Driving Therapeutic Demand and Innovation Globally?

Pediatric NF1 patients represent the largest initial treatment cohort, especially those with symptomatic, inoperable PNs that compromise function, cause pain, or distort anatomy. Adults with progressive PNs or those with a high risk of malignant peripheral nerve sheath tumor (MPNST) transformation are emerging as a secondary target population for therapeutic intervention. Multidisciplinary centers for neurofibromatosis, pediatric oncology hospitals, and clinical research organizations are leading patient recruitment, treatment trials, and data collection.

North America-especially the U.S.-remains the epicenter of NF1 research and drug approval activity, supported by institutions such as the NIH, Children’s Tumor Foundation, and leading university hospitals. Europe is also active, with research hubs in Germany, France, and the UK conducting collaborative trials through consortia like the European Reference Network for Rare Neurological Diseases. Asia-Pacific is increasingly involved in observational studies and early-phase trials, with growing awareness and diagnosis rates supporting demand. As genetic screening becomes more routine, global identification and management of PN patients is expected to expand significantly.

What Is Driving Long-Term Growth and Strategic Advancement in the Plexiform Neurofibromas Treatment Market?

The growth in the plexiform neurofibromas treatment market is driven by advances in genetic research, orphan drug policy incentives, and increased advocacy for rare disease therapies. As regulators offer expedited pathways for breakthrough treatments, pharmaceutical companies are investing in precision drugs that meet unmet clinical needs in NF1. Orphan drug designations, market exclusivity, and pediatric priority review vouchers are fueling innovation and reducing time-to-market for effective PN therapies.

Strategically, biopharma firms are forming partnerships with academic centers, patient advocacy organizations, and genomic data platforms to develop and commercialize therapies. Companion diagnostics, biomarker-driven trials, and real-world evidence registries are enhancing understanding of disease progression and treatment response. As awareness of NF1 grows within both the clinical and patient communities, early diagnosis and intervention are becoming priorities-fueling demand for novel therapies that offer meaningful tumor control, improved quality of life, and potential long-term remission. In this emerging therapeutic frontier, PNs represent not only a medical challenge but a gateway to innovation in treating complex genetic disorders.

SCOPE OF STUDY:

The report analyzes the Plexiform Neurofibromas Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants, Other Drug Classes); Demographic (Pediatric, Adult); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb
  • CureAge Therapeutics
  • Eli Lilly and Company
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Roche Holding AG
  • Sanofi S.A.
  • SpringWorks Therapeutics, Inc.
  • Takeda Pharmaceutical Company

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Plexiform Neurofibromas Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Genetic Research and Precision Medicine Propel Development of Targeted Therapies
    • Increasing Approval of Pediatric Drugs Strengthens Treatment Options for Plexiform Neurofibromas
    • Rising Healthcare Expenditure and Infrastructure Development Expand Access to Specialized Treatments
    • Growing Awareness and Improved Diagnostic Techniques Enhance Early Detection Rates
    • Strong Product Pipeline and Clinical Trials Accelerate Introduction of Novel Therapeutics
    • Outsourcing of Drug Development Activities Spurs Innovation in Treatment Modalities
    • Expansion of Orphan Drug Designations Encourages Investment in Rare Disease Therapies
    • Personalized Medicine Approaches Enhance Efficacy and Patient Outcomes
    • Integration of Multidisciplinary Care Models Improves Management of Complex Cases
    • Government Initiatives and Funding Support Research and Development Efforts
    • Collaboration Between Academic Institutions and Biopharmaceutical Companies Drives Innovation
    • Technological Advancements in Imaging and Surgical Techniques Improve Treatment Precision
    • Patient Advocacy and Support Groups Increase Awareness and Funding Opportunities
    • Regulatory Incentives and Fast-Track Approvals Facilitate Market Entry of New Treatments
    • Challenges in Treatment Accessibility and Affordability Highlight Need for Policy Reforms
    • Emergence of Gene Therapy and CRISPR Technologies Opens New Avenues for Treatment
    • Expansion of Telemedicine Services Enhances Patient Monitoring and Follow-Up Care
    • Development of Biomarkers Aids in Treatment Personalization and Monitoring
    • Increasing Prevalence of Neurofibromatosis Type 1 Drives Demand for Effective Therapies
    • Strategic Partnerships and Mergers Among Key Players Strengthen Market Position
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Plexiform Neurofibromas Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Plexiform Neurofibromas Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Plexiform Neurofibromas Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Selumetinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Selumetinib by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Selumetinib by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Steroidal Anti-Inflammatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Pediatric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Pediatric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Plexiform Neurofibromas Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Plexiform Neurofibromas Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Plexiform Neurofibromas Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Plexiform Neurofibromas Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Plexiform Neurofibromas Treatment by Drug Class - Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Plexiform Neurofibromas Treatment by Drug Class - Percentage Breakdown of Value Sales for Selumetinib, Non-Steroidal Anti-Inflammatory Drugs, Anticonvulsants and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Plexiform Neurofibromas Treatment by Demographic - Pediatric and Adult Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Plexiform Neurofibromas Treatment by Demographic - Percentage Breakdown of Value Sales for Pediatric and Adult for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Plexiform Neurofibromas Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Plexiform Neurofibromas Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제